CN112691091A

CN112691091A - Novel application of low-concentration carbolic acid

Info

Publication number: CN112691091A
Application number: CN202110085689.2A
Authority: CN
Inventors: 胡宝贤
Original assignee: Individual
Current assignee: Individual
Priority date: 2021-01-09
Filing date: 2021-01-22
Publication date: 2021-04-23

Abstract

The invention discloses application of low-concentration carbolic acid in preparation of a medicine for treating knee osteoarthritis. The invention adopts the low-concentration carbolic acid to treat knee osteoarthritis, has obvious treatment effect on the knee osteoarthritis, can maintain good state for a long time after treatment, can maintain more than 24 years to the maximum, has low recurrence rate, can greatly reduce the hospitalization times of patients and reduce the treatment cost; the carbolic acid has low price and small dosage, and can greatly reduce the treatment cost; has side effect and safe treatment.

Description

Novel application of low-concentration carbolic acid

Technical Field

The invention relates to the technical field of medicines, in particular to a new application of low-concentration carbolic acid.

Background

The knee osteoarthritis is a common disease and frequently encountered disease, is one of the diseases with the highest incidence in middle-aged and elderly people in China, and has the average incidence rate of 10%. Symptoms of osteoarthritis of the knee are manifested as pain and tenderness in the knee joint, swelling, or large amounts of synovial fluid inside; the knee joint stiffness, the movement disorder, can be accompanied with the atrophy of thigh muscles, and the eversion or inversion deformity can occur in the joints when the knee joint is serious, which seriously affects the labor capacity and the life quality of middle-aged and old people. At present, the treatment methods for knee osteoarthritis include acupuncture, physical therapy, electric heating, traditional Chinese medicine and small needle knife, but the knee osteoarthritis cannot be cured, most of the knee osteoarthritis is temporary and permanent, the problem of pain of a patient cannot be solved for a long time, severe patients can only be treated by surgery, joints can be replaced, and the effective rate is only about 50%.

Disclosure of Invention

According to more than 20 years of clinical work experience, the inventor finds that the low-concentration carbolic acid can be used for treating knee osteoarthritis, and has the advantages of remarkable treatment effect and no adverse reaction.

Therefore, based on the background, the invention provides a new application of low-concentration carbolic acid, in particular to an application in preparing a medicament for treating knee osteoarthritis.

The technical scheme of the invention is as follows:

the new application of the low-concentration carbolic acid is applied to preparing the medicine for treating knee osteoarthritis.

Further, the mass concentration of the low-concentration carbolic acid is 4-5%.

Further, the medicine is low-concentration carbolic acid compounded with lidocaine.

Further, the method for compounding the low-concentration carbolic acid with the lidocaine comprises the following steps: firstly, preparing a carbolic acid solution with the mass concentration of 8-10%, disinfecting for 30-40 minutes at high temperature and high pressure, cooling, and then preparing a carbolic acid lidocaine clarifying solution with the mass concentration of 4-5% of carbolic acid according to the volume ratio of 1: 1.

Furthermore, the above drugs are administered by local injection.

Further, the local injection mode is as follows: the patient bends the knee at 90 degrees and sits, skin iodophor at the bone spur part of the intercondylar spine of the tibia at the eyes of the double knees or the single knee is disinfected, and 0.5 to 0.75 ml of iodine is injected into the left and the right eyes of the knee respectively. After injection, the local part has no bleeding or the wound paste is stuck after bleeding stops to protect the needle eye.

Carbolic acid, also known as phenol, is highly corrosive at high concentrations, but is slightly corrosive at 3-6% concentrations, has good bactericidal, anti-inflammatory effects, and can coagulate all protein-containing cells, enzymes, and inflammatory substances, deactivating them. When osteoarthritis occurs, the cartilage surface of the cartilage of the thin bone joint is abraded and broken due to stimulation and friction of bone spurs to form inflammation, so that the surrounding soft tissues are subjected to inflammation change, and synovial fluid tissues in the joint cavity are subjected to inflammatory exudation to form a series of symptoms. The low-concentration carbolic acid can repair the inflammatory fracture surface of the articular cartilage surface by eliminating inflammation, can solidify inflammatory cells, eliminate inflammatory factors in synovial fluid and remove the inflammation of the articular soft tissue.

Due to the acidic property of carbolic acid and the action of coagulated protein, the new bone spur cartilage cells can be coagulated, shrunk and disappeared for the bone spur cartilage part with vigorous hyperplasia. The calcified bone portions of the base promote softening thereof.

Preferably, in the invention, carbolic acid and lidocaine are compounded, and the added lidocaine can play a role in: the stimulation of phenol to tissues in the joint cavity is relieved; secondly, the permeability of the carbolic acid in the joint cavity is increased; and relieving the irritation and pain of phenol during injection.

By adopting the technical scheme, the beneficial effects are as follows:

the invention applies the carbolic acid with low concentration to the treatment of knee osteoarthritis, has obvious treatment effect on the knee osteoarthritis, can maintain good state for a long time after treatment, can maintain more than 24 years to the maximum, has low recurrence rate, can greatly reduce the hospitalization times of patients and reduce the treatment cost; the carbolic acid has low price and small dosage, and can greatly reduce the treatment cost; has no side effect and safe treatment.

Detailed Description

In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are some embodiments of the present invention, but not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Example 1: the new application of the low-concentration carbolic acid in preparing the medicine for treating knee osteoarthritis. .

The mass concentration of the low-concentration carbolic acid is 4-5%.

In this embodiment, the drug is a low concentration carbolic acid compounded with lidocaine.

The method for compounding the low-concentration carbolic acid with the lidocaine comprises the following steps: firstly, preparing a carbolic acid solution with the mass concentration of 8-10%, disinfecting for 30-40 minutes at high temperature and high pressure, cooling, and then preparing a carbolic acid lidocaine clarifying solution with the mass concentration of 4-5% of carbolic acid according to the volume ratio of 1: 1.

The injection mode of the medicine is as follows: the patient bends the knee at 90 degrees and sits, skin iodophor at the bone spur part of the intercondylar spine of the tibia at the eyes of the double knees or the single knee is disinfected, and 0.5 to 0.75 ml of iodine is injected into the left and the right eyes of the knee respectively. After injection, the local part has no bleeding or the wound paste is stuck after bleeding stops to protect the needle eye. After injection, the patient was unable to wash the needle eye with water within three days.

The low-concentration carbolic acid of the invention can not exceed 20 ml per injection dose. The typical treatment cycle is: the patient is injected with carbolic acid solution once a week, with 6 or 8 or 10 times per treatment course. The treatment period is generally one treatment course.

(1) The invention uses the taboo:

contraindicated for people with stone charcoal acid allergy

② the forbidden use for severe narrow joint space or gap disappearance of knee osteoarthritis joint

And the active stage or chemotherapy stage of tumor is forbidden.

Patients with hematopathy including leukopenia and thrombocytopenia are forbidden.

Fifthly, the medicine is forbidden for patients with liver and kidney diseases and dysfunction.

Sixthly, the patient with serious heart disease including myocardial infarction and serious arrhythmia is forbidden.

And knee osteoarthritis complicated with meniscus injury.

(2) Clinical application data

Summary of treatment status for 312 patients from 1996 to 2020 who were at my visit, 312 patients were at age 35-85 years at the time of treatment, course: 7 days to 27 years. 261 women, 51 men, 176 double knee joint lesions, 62 left knee joints and 74 right knee joints.

Before treatment, the patients are subjected to knee joint photography, knee joint CT, routine blood examination, electrocardiogram, liver and kidney function and routine blood/urine examination, and medication contraindications are excluded.

(ii) diagnostic criteria for knee osteoarthritis symptoms

a. Mild: the knee joint is bounced, the joint is only painful when going upstairs or downstairs or going downslopes, and no discomfort is caused when the user walks on a flat road. The x-ray film shows the formation of small bony spurs (osteophytes) on the intercondylar spine of the tibia. There were 16 patients in this group.

b. Medium: on a mild basis, pain occurs when starting, the patient turns better after moving, pain occurs after a long period of movement, and even mobility pain occurs when the patient is lying. Mobility is limited. Knee joint popliteal fossa distending pain sensation. Stiff or flexed joints. X-ray pictures show the formation of bony spurs on the superior and marginal tibial intercondylar spine, or a slightly narrower gap between the relevant segments. 284 cases are included in this group.

And (3) severe degree: mobility pain in the recumbent position, pain markedly worsened during activity. Activity is significantly limited. In this group, 12 cases of 12 cases have the symptoms of narrow gaps and inward or outward deviation of the joints due to the formation of bony spurs at various positions on the joints.

Effective standard of treatment

a. The method is completely effective: after treatment, the original symptoms are basically disappeared.

b. And partial effective: after treatment, the knee joint still has a little stiffness, pain or limited flexion when walking

c. Complete invalidation: after treatment, symptoms did not improve within half a year.

In 312 patients in the group, after the injection is finished, the total effective number and the partial effective number are 272, the safe ineffective number is 40, the total effective rate is 87%, and the ineffective rate is 13%.

All the above treatment cases are one-time treatment cases.

③ treatment of follow-up visit

Of the 312 patients mentioned above, there were 112 patients treated in my places of 1996-2010, followed by 12 months of 2020, with 12 patients in mild, 96 in moderate and 6 in severe cases.

a. Mild patients: only 1 patient relapsed at 5 years post-treatment, and were re-injected 6 times, to date normal, with the remaining patients remaining normal.

b. Moderate patients: the disease recurs 8 years after 2 patients are treated, and after 6-8 injections, 1 patient is normal and 1 patient is ineffective. 1 case relapsed 10 years after treatment, and improved 8 times after injection, 1 case relapsed 20 years after treatment, and 8 times after injection, and improved pain; the rest of the patients remained normal.

c. Severe patients: the patients in the group are older, have more related diseases and serious knee joint diseases, 1 patient is 80 years old, the knee joint condition is well followed up 4 years after treatment, and the heart failure is eliminated 6 years later due to hypertension. 1 patient relapsed 8 years after treatment, and had obvious gap stenosis of knee joint, and was treated symptomatically. The better state is maintained after 4 cases of treatment. 2 patients maintain more than 5 years to the present, and before 2010, the fixed-line telephone of the patients is cured and the follow-up visit is lost; the rest of the patients remained normal.

Maintaining remission time

Of the 312 patients mentioned above:

a. there were 3 patients who relapsed within 1-5 years after treatment, 1 of which was mild, and returned to normal after treatment again; 2 patients with severe disease, after recurrence, had severe joint disease before treatment and had poor secondary treatment effect.

b. There were 8 patients who relapsed within 6-20 years after treatment, 2 of which relapsed at 8 years after treatment, 1 was normal and 1 was not effective until now after 6-8 injections; 1 case recurs 20 years after treatment, 8 injections improve pain; in 3 cases, the disease recurred in the 10 th year after treatment, and recovered to normal after 6 injections.

c. After treatment, in 2 patients who relapse within the 21 st to 24 th years, the joint disease is serious before treatment, and the treatment effect is poor again.

Among 112 patients treated in my places in 1996-2010, 53 patients who remained without recurrence for 10-24 years after treatment, and 26 patients who remained without recurrence for 5-9 years after treatment.

In conclusion, the treatment conditions of 312 patients in the group show that the one-time cure of the invention has high effective rate, low recurrence rate and long maintenance time after treatment, and at present, the treatment can be maintained for more than 24 years without recurrence, and the curative effect is remarkable.

(3) When the invention is used for treatment, the following reactions can exist, and are all normal:

1. the discomfort and pain of the knee joint appear 6 to 8 hours after the local injection, and generally the pain is gradually relieved after lasting for 3 to 4 days. By 6-7 days, the drug reaction basically disappears. Few patients have obvious local pain even lasting for one week, and symptoms can be relieved by ordering the patients to take the non-steroidal anti-inflammatory drugs for 3-4 consecutive days.

2. Swelling feeling: after 6-8 hours after injection, the knee joint is swollen and pain is mixed, and the hot compress is carried out when the patient is in bed for 2-3 days, so that the swelling is relieved. And swelling in a few patients may continue for the treatment period. But does not affect the treatment.

3. Stiff feeling: joint stiffness and flexion and extension limitation appear in the treatment period. Generally, the stiffness is relieved after 3 to 4 days, and the stiffness disappears after 6 to 7 days.

4. And (3) allergic reaction: and individual patients have anaphylactic reaction to phenol, and in more than twenty years of clinical use, the authors only find that 2 patients have anaphylactic reaction, mainly show that the injection part and the part below the knee joint are obviously red and swollen, painful and limited in activity, and the patients are subjected to blood circulation promotion after being subjected to double-lower-limb B-ultrasound to eliminate angiopathy, and the symptoms disappear after the anti-inflammatory and anti-allergic treatment for one week. 1 case of pudendum itch with water, and anti-allergic treatment recovery.

5. Joint weakness: a few patients have weak joint movement after injection, and the discomfort disappears after 3-4 times of continuous injection. Some patients need to continue until 1-2 months after treatment, and symptoms disappear.

The above is the possible reaction when the low-concentration carbolic acid is used for treating knee osteoarthritis. However, these responses gradually disappear as the therapeutic effect is clearly manifested. None of the cases gave a persistent or long-term response.

(4) Liver and kidney function, electrocardiogram and hemogram detection: the liver and kidney function, electrocardiogram and blood routine of more than 400 patients before treatment are continuously monitored, the physical examination result every year is continuously tracked for three years after treatment, and no abnormal index related to the use of carbolic acid is found.

The present invention and the embodiments thereof have been described above, but the description is not limited thereto, and the embodiments shown in the above embodiments are only one of the embodiments of the present invention, and the actual configuration is not limited thereto. In summary, those skilled in the art should appreciate that they can readily use the disclosed conception and specific embodiments as a basis for designing or modifying other structures for carrying out the same purposes of the present invention without departing from the spirit and scope of the invention as defined by the appended claims.

Claims

1. The new application of the low-concentration carbolic acid is characterized by being applied to the preparation of the medicine for treating knee osteoarthritis.

2. The use of claim 1, wherein the mass concentration of the low-concentration carbolic acid is 4-5%.

3. The use of claim 1, wherein the drug is low concentration carbolic acid in combination with lidocaine.

4. The use of claim 3, wherein the method for compounding the low-concentration carbolic acid with the lidocaine is as follows: firstly, preparing a carbolic acid solution with the mass concentration of 8-10%, disinfecting for 30-40 minutes at high temperature and high pressure, cooling, and then preparing a carbolic acid lidocaine clarifying solution with the mass concentration of 4-5% of carbolic acid according to the volume ratio of 1: 1.

5. The use according to claim 3, wherein the medicament is administered by local injection.